Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary di...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipson, David A., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, Lange, Peter, Lomas, David A., Lettis, Sally, Manchester, Pamela, Martin, Neil, Midwinter, Dawn, Morris, Andrea, Pascoe, Steven J., Singh, Dave, Wise, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301738/
https://www.ncbi.nlm.nih.gov/pubmed/32162970
http://dx.doi.org/10.1164/rccm.201911-2207OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301738/
https://www.ncbi.nlm.nih.gov/pubmed/32162970
http://dx.doi.org/10.1164/rccm.201911-2207OC

Ejemplares similares